Celltrion’s Biosimilar Rituximab Edges Ahead With Korean Approval
Celltrion has edged ahead of its competitors in the close race to develop biosimilar versions of rituximab with the approval of its product in South Korea, which could help speed development in other markets where the South Korean firm is also seeking approvals.
You may also be interested in...
For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.
South Korean analysts and pharma firms are generally viewing Donald Trump's win in the US presidential election as positive for the sector, which is stepping up efforts to enter global markets including the US.
Poland’s biotech Mabion is racing to the European biosimilar market with a biosimilar rituximab, but is up against multinational biosimilar companies like Sandoz and South Korea’s Celltrion, and will likely need a strong commercialization partner outside its home market.